Reviva Pharmaceuticals Holdings, Inc. (RVPH)Healthcare | Biotechnology | Cupertino, United States | NasdaqCM
0.85 USD
-0.02
(-2.746%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.87 +0.02 (2.365%) ⇧ (April 17, 2026, 6:28 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:07 a.m. EDT
RVPH is a high-risk biotech stock with deteriorating fundamentals (negative EPS, negative CAGR, massive stock split) and a market that has priced in severe volatility. The options market is screaming 'downside' via the heavy put IV skew, correctly identifying that while analysts dream of a successful Phase 3 trial (targeting $58), the math behind the balance sheet and current cash burn suggests a bleak near-to-intermediate term future without further dilution or a major clinical surprise. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.736468 |
| MSTL | 0.903159 |
| AutoARIMA | 0.924424 |
| AutoETS | 0.924426 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 216.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.035 |
| Excess Kurtosis | -1.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.705 |
| Market Cap | 10,888,821 |
| Forward P/E | -1.03 |
| Beta | 0.64 |
| Website | https://www.revivapharma.com |
As of April 19, 2026, 12:07 a.m. EDT: Options data reveals an extreme skew in pricing. Implied Volatility (IV) for Puts is significantly elevated (2.4x–5.2x average) compared to Calls (0.59x–0.42x average). This 'call put skew' indicates speculators are heavily positioning for downside protection. While Open Interest (OI) sits at a psychological floor of 0.50, the high IV on puts suggests a strong hedging or bearish inventory build, while call buyers are pricing in low volatility for upside moves.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9433333 |
| Address1 | 10,080 N. Wolfe Road |
| Address2 | Suite SW3-200 |
| All Time High | 302.0 |
| All Time Low | 0.59 |
| Ask | 0.8651 |
| Ask Size | 7 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 620,380 |
| Average Daily Volume3 Month | 535,777 |
| Average Volume | 535,777 |
| Average Volume10Days | 620,380 |
| Beta | 0.642 |
| Bid | 0.8397 |
| Bid Size | 7 |
| Book Value | 1.472 |
| City | Cupertino |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.85 |
| Current Ratio | 2.076 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.923 |
| Day Low | 0.85 |
| Debt To Equity | 4.705 |
| Display Name | Reviva Pharmaceuticals |
| Earnings Timestamp | 1,774,873,800 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | -3,143,096 |
| Eps Current Year | -2.48 |
| Eps Forward | -0.825 |
| Eps Trailing Twelve Months | -5.48 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 408 904 6270 |
| Fifty Day Average | 2.7728 |
| Fifty Day Average Change | -1.9228 |
| Fifty Day Average Change Percent | -0.6934506 |
| Fifty Two Week Change Percent | -94.333336 |
| Fifty Two Week High | 23.2 |
| Fifty Two Week High Change | -22.35 |
| Fifty Two Week High Change Percent | -0.96336204 |
| Fifty Two Week Low | 0.59 |
| Fifty Two Week Low Change | 0.26000005 |
| Fifty Two Week Low Change Percent | 0.44067806 |
| Fifty Two Week Range | 0.59 - 23.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,539,869,400,000 |
| Float Shares | 11,173,979 |
| Forward Eps | -0.825 |
| Forward P E | -1.0303031 |
| Free Cashflow | -17,137,860 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01942 |
| Held Percent Institutions | 0.15243 |
| Implied Shares Outstanding | 12,810,377 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,014,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California. |
| Long Name | Reviva Pharmaceuticals Holdings, Inc. |
| Market | us_market |
| Market Cap | 10,888,821 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_126911636 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -19,864,902 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,888,820 |
| Number Of Analyst Opinions | 5 |
| Open | 0.9 |
| Operating Cashflow | -24,594,644 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 408 501 8881 |
| Post Market Change | 0.020099998 |
| Post Market Change Percent | 2.3647056 |
| Post Market Price | 0.8701 |
| Post Market Time | 1,776,464,914 |
| Previous Close | 0.874 |
| Price Eps Current Year | -0.34274194 |
| Price Hint | 4 |
| Price To Book | 0.5774457 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.985 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.024 |
| Regular Market Change Percent | -2.74599 |
| Regular Market Day High | 0.923 |
| Regular Market Day Low | 0.85 |
| Regular Market Day Range | 0.85 - 0.923 |
| Regular Market Open | 0.9 |
| Regular Market Previous Close | 0.874 |
| Regular Market Price | 0.85 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 781,235 |
| Return On Assets | -0.80347 |
| Return On Equity | -4.1996703 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,810,377 |
| Shares Percent Shares Out | 0.1432 |
| Shares Short | 1,834,224 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 993,765 |
| Short Name | Reviva Pharmaceuticals Holdings |
| Short Percent Of Float | 0.1469 |
| Short Ratio | 2.02 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVPH |
| Target High Price | 140.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 58.2 |
| Target Median Price | 40.0 |
| Total Cash | 14,438,792 |
| Total Cash Per Share | 1.127 |
| Total Debt | 406,875 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.6872 |
| Two Hundred Day Average Change | -6.8372 |
| Two Hundred Day Average Change Percent | -0.8894266 |
| Type Disp | Equity |
| Volume | 781,235 |
| Website | https://www.revivapharma.com |
| Zip | 95,014 |